High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke
| Autor: | Diederik W.J. Dippel, Dingeman C. Rijken, M. P. M. Maat, Mary-Lou P. J. van Goor, Frank W.G. Leebeek, Ana H. C. Guimarães, G. J. Brouwers |
|---|---|
| Přispěvatelé: | Hematology, Neurology |
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Risk Carboxypeptidase B2 medicine.medical_specialty Genotype medicine.medical_treatment White People Brain Ischemia Internal medicine Fibrinolysis medicine Humans Prospective Studies Stroke Aged Molecular Epidemiology Polymorphism Genetic business.industry Acute-phase protein Hematology Odds ratio Middle Aged medicine.disease Thrombosis Confidence interval Surgery Europe Kinetics Quartile Case-Control Studies Conventional PCI Cardiology Female business |
| Zdroj: | Journal of Thrombosis and Haemostasis, 3(10), 2211-2218. Wiley-Blackwell Publishing Ltd |
| ISSN: | 1538-7836 1538-7933 |
| DOI: | 10.1111/j.1538-7836.2005.01484.x |
| Popis: | Summary. Background and objective: Several studies have suggested that thrombin-activatable fibrinolysis inhibitor (TAFI) levels are associated with the risk of arterial thrombosis, but results have been contradictory. We studied functional TAFI levels and TAFI gene polymorphisms in 124 patients with a recent ischemic stroke and 125 age- and sex-matched controls to establish the role of TAFI in ischemic stroke. Methods and results: Functional TAFI levels, defined as TAFI-related retardation (RT), the difference in clot lysis time (LT) in the absence or presence of a specific activated TAFI inhibitor (potato carboxypeptidase inhibitor [PCI]), were higher in patients than controls (19.5 ± 4.2 vs. 17.7 ± 3.7 min, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text